Details for Patent: 11,413,360
✉ Email this page to a colleague
Which drugs does patent 11,413,360 protect, and when does it expire?
Patent 11,413,360 protects POSLUMA and is included in one NDA.
This patent has seventeen patent family members in thirteen countries.
Drugs Protected by US Patent 11,413,360
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS WHO ARE CANDIDATES FOR INITIAL DEFINITIVE THERAPY | ⤷ Try a Trial | |||
| Blue Earth | POSLUMA | flotufolastat f-18 gallium | SOLUTION;INTRAVENOUS | 216023-001 | May 25, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED RECURRENCE BASED ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN (PSA) LEVEL | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,413,360
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018308699 | ⤷ Try a Trial | |||
| Australia | 2024200440 | ⤷ Try a Trial | |||
| Brazil | 112020001785 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
